Endocyte

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

You can watch Endocyte and buy or sell other stocks, options, and ETFs commission-free!

About ECYT

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. 

CEO
Michael A. Sherman, MBA
CEOMichael A. Sherman, MBA
Employees
Employees
Headquarters
West Lafayette, Indiana
HeadquartersWest Lafayette, Indiana
Founded
1995
Founded1995
Employees
Employees

ECYT Key Statistics

Market cap
1.95B
Market cap1.95B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.68M
Average volume1.68M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$24.00
52 Week high$24.00
52 Week low
$2.81
52 Week low$2.81
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.